As filed with the Securities and Exchange Commission on March 13, 2020
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Miragen Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
|
47-1187261
|
|
(State or other jurisdiction of
Incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
6200 Lookout Road
Boulder, CO 80301
(Address of principal executive offices) (Zip code)
Miragen Therapeutics, Inc. 2016 Equity Incentive Plan
Miragen Therapeutics, Inc. 2016 Employee Stock Purchase Plan
(Full title of the plan)
William S. Marshall, Ph.D.
President and Chief Executive Officer
6200 Lookout Road
Boulder, CO 80301
(303) 531-5952
(Name and address of agent for service) (Telephone number, including area code, of agent for service)
Brent D. Fassett
Cooley LLP
380 Interlocken Crescent, Suite 900
Broomfield, CO 80021
(720) 566-4000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
|
|
|
|
Large accelerated filer
|
|
¨
|
|
Accelerated filer
|
|
x
|
|
Non-accelerated filer
|
|
¨
|
|
Smaller reporting company
|
|
x
|
|
|
|
|
|
Emerging growth company
|
|
¨
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title of Securities
to be Registered
|
|
Amount
to be
Registered(1)
|
|
Proposed
Maximum
Offering Price
per Share(2)
|
|
Proposed
Maximum
Aggregate
Offering Price(2)
|
|
Amount of
Registration Fee
|
|
Common Stock, par value $0.01 per share
|
|
|
|
|
|
|
|
|
|
|
– Shares reserved for future grant under the 2016 Equity Incentive Plan
|
|
1,394,475
|
|
(3
|
)
|
|
$0.71
|
|
$990,077.25
|
|
$128.52
|
|
– Shares reserved for future grant under the 2016 Employee Stock Purchase Plan
|
|
348,618
|
|
(4
|
)
|
|
$0.71
|
|
$247,518.78
|
|
$32.13
|
|
Total
|
|
1,743,093
|
|
|
|
N/A
|
|
$1,237,596.03
|
|
$160.65
|
|
|
|
(1)
|
Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of Registrant’s common stock, par value $0.01 per share (“Common Stock”), that become issuable under the Registrant’s 2016 Equity Incentive Plan (the “2016 Plan”) or 2016 Employee Stock Purchase Plan (the “2016 ESPP”) by reason of any stock dividend, stock split, recapitalization or other similar transaction that results in an increase in the number of outstanding shares of Registrant’s Common Stock.
|
|
(2)
|
Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) promulgated under the Securities Act. The offering price per share and the aggregate offering price are based upon the average of the high and low prices of the Common Stock as reported on The Nasdaq Capital Market on March 9, 2020.
|
|
(3)
|
Represents an automatic increase to the number of shares of Common Stock available for issuance under the 2016 Plan effective January 1, 2020. Shares available for issuance under the 2016 Plan were previously registered on a registration statement on Form S-8 filed with the Securities and Exchange Commission (the “SEC”) on February 17, 2017 (Registration No. 333-216112).
|
|
(4)
|
Represents an automatic increase to the number of shares of Common Stock available for issuance under the 2016 ESPP effective January 1, 2020. Shares available for issuance under the 2016 ESPP were previously registered on a registration statement on Form S-8 filed with the SEC on February 17, 2017 (Registration No. 333-216112).
|
REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION
Pursuant to General Instruction E of Form S-8, Miragen Therapeutics, Inc., a Delaware corporation (the “Registrant”), is filing this Registration Statement with the Securities and Exchange Commission (the “SEC”) to register 1,394,475 additional shares of the Registrant’s common stock, par value $0.01 per share (“Common Stock”) under the Registrant’s 2016 Equity Incentive Plan and 348,618 additional shares of Common Stock under the Registrant’s 2016 Employee Stock Purchase Plan pursuant to the provisions of those plans providing for an automatic increase in the number of shares reserved for issuance under such plans. This Registration Statement hereby incorporates by reference the contents of the Registrant’s Registration Statement on Form S-8 filed with the SEC on February 17, 2017 (Registration No. 333-216112).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ITEM 8.
|
EXHIBITS.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exhibit
No.
|
|
Exhibit Description
|
|
Schedule
/ Form
|
|
File Number
|
|
Exhibit
|
|
Filing Date
|
|
|
|
|
|
|
|
|
4.1
|
|
|
|
10-Q
|
|
001-36483
|
|
3.1
|
|
August 14, 2014
|
|
|
|
|
|
|
|
|
4.2
|
|
|
|
S-4
|
|
333-214893
|
|
3.3
|
|
December 2, 2016
|
|
|
|
|
|
|
|
|
4.3
|
|
|
|
8-K
|
|
001-36483
|
|
3.1
|
|
February 13, 2017
|
|
|
|
|
|
|
|
|
4.4
|
|
|
|
8-K
|
|
001-36483
|
|
3.2
|
|
February 13, 2017
|
|
|
|
|
|
|
|
|
4.5
|
|
|
|
8-K
|
|
001-36483
|
|
3.4
|
|
February 13, 2017
|
|
|
|
|
|
|
|
|
4.6
|
|
|
|
10-Q
|
|
001-36483
|
|
3.1
|
|
August 15, 2016
|
|
|
|
|
|
|
|
|
4.7
|
|
|
|
8-K
|
|
001-36483
|
|
3.3
|
|
February 13, 2017
|
|
|
|
|
|
|
|
|
4.8
|
|
|
|
S-1
|
|
333-194668
|
|
4.1
|
|
March 19, 2014
|
|
|
|
|
|
|
|
|
5.1*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.1*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.2*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.1*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.1
|
|
|
|
S-4
|
|
333-214893
|
|
10.37
|
|
December 2, 2016
|
|
|
|
|
|
|
|
|
99.2
|
|
|
|
S-4
|
|
333-214893
|
|
10.38
|
|
December 2, 2016
|
|
|
|
|
|
|
|
|
99.3
|
|
|
|
S-4
|
|
333-214893
|
|
10.39
|
|
December 2, 2016
|
|
*
|
Filed herewith
|
SIGNATURES
The Registrant. Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boulder, State of Colorado, on March 13, 2020.
|
|
|
|
|
|
|
MIRAGEN THERAPEUTICS, INC.
|
|
|
|
/s/ Jason A. Leverone
|
|
Jason A. Leverone
|
|
Chief Financial Officer, Treasurer and Secretary
|
POWER OF ATTORNEY
Know All Persons By These Presents, that each person whose signature appears below constitutes and appoints William S. Marshall and Jason A. Leverone, and each or any one of them, as his or her true and lawful attorney-in-fact and agent, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to sign any registration statement for the same offering covered by this Registration Statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act of 1933, and all post-effective amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
|
|
|
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
|
/s/ William S. Marshall
|
|
President, Chief Executive Officer, and Director
|
|
March 13, 2020
|
|
William S. Marshall, Ph.D.
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
|
|
/s/ Jason A. Leverone
|
|
Chief Financial Officer, Treasurer, and Secretary
|
|
March 13, 2020
|
|
Jason A. Leverone
|
|
(Principal Financial Officer; Principal Accounting Officer)
|
|
|
|
|
|
|
|
|
|
/s/ Jeffrey S. Hatfield
|
|
Chairman of the Board
|
|
March 13, 2020
|
|
Jeffrey S. Hatfield
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Christopher Bowden
|
|
Director
|
|
March 13, 2020
|
|
Christopher Bowden, M.D.
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Thomas E. Hughes
|
|
Director
|
|
March 13, 2020
|
|
Thomas E. Hughes, Ph.D.
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Kevin Koch
|
|
Director
|
|
March 13, 2020
|
|
Kevin Koch, Ph.D.
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Arlene M. Morris
|
|
Director
|
|
March 13, 2020
|
|
Arlene M. Morris
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Joseph L. Turner
|
|
Director
|
|
March 13, 2020
|
|
Joseph L. Turner
|
|
|
|
|
|
|
|
|
|
|